If you build medical software or health AI (SaMD), the tooling choice often collapses into two families: a native ALM/eQMS platform you migrate into, or a compliance layer on top of the development flow and QMS you already run. The real pain is rarely “missing features”. It is document rework, lost sync between Jira, Git and the QMS, and the risk of gaps before a certification audit.
This article, from the QARA PULSE lens, sets operational criteria (ALM and traceability, QMS, SaMD/AI fit, EU vs FDA focus, implementation) to decide whether Qapsule + eQMS in your tools is the right fit. The table below situates Qapsule against Ketryx and Matrix Req as market reference points. Judgments draw on public positioning and field experience (August 2026). They do not replace a demo or a review of your own requirements.
Qapsule in brief
Qapsule is QARA PULSE's continuous compliance platform. It orchestrates evidence and traceability around tools you already use, without imposing an ALM/eQMS suite. The common field pair: QARA PULSE experts (strategy, CE marking, eQMS) plus a system that stays after the engagement.
On your stack
Connects to Jira, Git, Notion, Atlassian, Drive / SharePoint and neighbouring tools. Goal: one source of truth, no duplicate data entry.
eQMS in your tools
CAPA, training and doc control deployed in the client stack via the QARA PULSE service, then orchestrated continuously by Qapsule.
EU / France anchor
Frame: ISO 13485, IEC 62304, ISO 14971, MDR/IVDR. France hosting (OVHcloud). EU-first market priority.
Comparison table
Key: Yes Partial No . Category-level judgments from public positioning (August 2026). Always validate in a demo.
| Criterion | Ketryx | Matrix Req | Qapsule |
|---|---|---|---|
| Product logic | Compliance / ALM layer on DevTools | Native ALM/PLM + eQMS suite | Continuous compliance layer on stack + eQMS |
| Native requirements & design control | Partial often via DevTools | Yes core product | Partial orchestrates; does not replace ALM |
| Native eQMS (CAPA, training, doc control…) | Partial enforcement in the Dev flow | Yes native suite | Yes* via eQMS in your tools |
| Layer on Jira / Git / product tools | Yes core product | Partial integrations available | Yes |
| No forced migration into an ALM/eQMS suite | Partial depends on DevOps stack | No often aims at consolidation | Yes |
| Traceability & audit-ready evidence | Yes | Yes | Yes |
| ISO 13485 · IEC 62304 · MDR / IVDR frame | Yes | Yes | Yes |
| FDA / 21 CFR Part 11 orientation | Yes strong positioning | Yes publicly stated | Partial EU-first |
| SaMD / software & medical AI fit | Yes | Yes also hardware / combination | Yes software / health AI focus |
| France / EU hosting posture | Partial confirm in contract | Partial confirm in contract | Yes OVHcloud FR |
| Regulatory expert accompaniment tied to the product | Partial CS / product | Partial CS / migration | Yes QARA PULSE firm |
| Public pricing | No quote / demo | No quote / demo | No scoped to context |
* Yes* for Qapsule: the eQMS need (CAPA, training, doc control…) is covered with QARA PULSE's eQMS in your tools service, deployed in the client stack, rather than via a native eQMS suite. Qapsule then orchestrates continuous evidence and traceability.
Qapsule's targeted gains
On the QARA PULSE product page, Qapsule's targeted gains are stated as: update evidence up to ×4 faster, centralise 100% of evidence in a traceable way inside Qapsule, and aim for 0 duplicate data entry (one source of truth). These are design targets, not a universal contractual guarantee. Outcomes depend on stack, document discipline and initial scoping.
Those figures mainly help stress-test an economic hypothesis. If the pain is document rework and lost sync between product tools and the QMS, an orchestration layer often costs less (and less risk before CE) than full ALM/eQMS consolidation. On the firm side, QARA PULSE also publishes accompaniment results (for example +35 projects, 85% time-to-market reduction on published indicators). Those measure the experts + method package, not the tool alone.
When Qapsule + eQMS in your tools is the right fit
- You are a SaMD / health AI team, especially EU / France, with a CE or notified-body audit timeline.
- Jira, Git and (often) an eQMS or document sprawl already exist; you refuse a forced migration.
- You want to structure the QMS where people already work (CAPA, training, doc control) via eQMS in your tools.
- You need continuous audit-ready MDR/IVDR evidence, not only a static requirements system of record.
- You want a system that stays after the engagement, paired with experts who know the file through to the notified body.
It is not the right pick if you explicitly want an all-in-one ALM/eQMS that replaces the stack. In that case a native suite remains a separate path; the table above helps situate the product-logic gaps.
FAQ
Do you need to migrate to an ALM / eQMS suite for SaMD?
Not necessarily. Many SaMD teams already run Jira, Git and a QMS. Migrating to a native suite costs time, adoption and audit risk. Qapsule industrialises evidence and traceability on the stack you already have; the eQMS in your tools service structures CAPA, training and doc control where people already work. A single ALM suite only makes sense if you truly lack a system of record and accept consolidation.
Does Qapsule replace an eQMS?
No. Qapsule orchestrates continuous compliance (evidence, traceability, product / quality sync). The eQMS need is covered with QARA PULSE's eQMS in your tools deployment, in the client stack. The pair fits when you want an operational QMS without an imposed suite, then audit-ready evidence on an ongoing basis.
How does Qapsule work with Jira, Git and an existing eQMS?
Qapsule connects to tools you already use (Jira, Git, Notion, Atlassian, Drive / SharePoint, and similar) and centralises evidence in a traceable way, without duplicate data entry. Published targets are updating evidence up to ×4 faster, centralising 100% of evidence in Qapsule, and aiming for 0 duplicate entry. Outcomes depend on stack, document discipline and initial scoping. See the Qapsule page.
Is Qapsule a fit when the priority market is the EU (MDR / IVDR)?
Yes, that is the most common use case. Qapsule and QARA PULSE are anchored in ISO 13485, IEC 62304, ISO 14971 and MDR/IVDR, with France hosting (OVHcloud) and accompaniment through to the notified body. An FDA / 21 CFR Part 11 posture can be scoped under a custom quote, depending on project scope. To situate this criterion against other market references, see the comparison table above.
How do you frame the tooling choice in 30 minutes with QARA PULSE?
Four points are enough: current stack (Jira, Git, eQMS), priority market (EU, FDA, both), need for a native eQMS versus eQMS in your tools, and CE / audit timeline. Contact us or book a slot: a call often clarifies whether Qapsule + eQMS in your tools + experts is the fit, or whether suite consolidation is truly required.
Why keep QARA PULSE on the shortlist
For many European software teams, a concrete trio makes the difference: Qapsule for continuous compliance, eQMS in your tools for a QMS without an imposed suite, and experts who know the CE file through to the notified body. Less migration, more synchronised evidence, France hosting, and a system that does not disappear when the engagement ends.
If your shortlist starts from the assumption that you need a native suite, add Qapsule to challenge that reflex. Often the better fit is to keep what the team already uses, and industrialise compliance around it.
Category analysis as of August 2026, based on public positioning and QARA PULSE field experience. Not an exhaustive feature benchmark, and not a claim about unpublished roadmaps or certifications. Always verify capabilities, hosting and contract terms with each vendor.